Linda Shui
Women's Health · Walnut Creek, CANPI 1578683124
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 109 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Among women's health clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$399
- Pfizer$204
- Astellas Pharma US Inc$203
- Biogen$163
- Mayne Pharma Commercial LLC$139
- Avion Pharmaceuticals$137
- plus $738 from 14 others
What the payments were for
- Food & beverage$1,83292%
- Education$1528%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $399 |
| Pfizer | 11 | $204 |
| Astellas Pharma US Inc | 5 | $203 |
| Biogen | 6 | $163 |
| Mayne Pharma Commercial LLC | 16 | $139 |
| Avion Pharmaceuticals | 13 | $137 |
| Millicent US Inc | 6 | $129 |
| Organon | 6 | $123 |
| Exact Sciences | 6 | $109 |
| Myovant Sciences Inc. | 4 | $84 |
| Agile Therapeutics, Inc. | 4 | $74 |
| Bayer | 2 | $45 |
| Therapeuticsmd, Inc. | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Exeltis, USA Inc. | 1 | $24 |
| Evofem Biosciences, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Merck | 1 | $16 |
| Ascend Therapeutics US, LLC | 1 | $14 |
| Mylan Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,984 in reported general payments places this provider in the 90th percentile of 480 women's health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EstringEstradiol | 12 | $6,360 |
| Estradiol | 61 | $5,441 |
| PremarinEstrogens, Conjugated | 11 | $4,722 |
| YuvafemEstradiol | 15 | $2,699 |
| Estradiol (Once Weekly)Estradiol | 15 | $1,842 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEstring, Premarin | $204 | $11,08223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 480 women's health providers in California.
Other women's health in Walnut Creek
- Patricia GeraghtyWalnut Creek$26K
- Barbara DehnMountain View$87K
- Zaruhi HarutyunyanWest Hollywood$55K
- Roberta MoradfarWest Hollywood$30K
- Katherine KetzStockton$26K
- Debbie BarishBerkeley$16K
- Raisa HowardEl Segundo$11K
- Mary FesselWoodland$8K
- Kay MorelandSanta Maria$6K
- Allison AlixOrange$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.